Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HPC Mobilization in ICL Patients and Healthy Controls
NCT02015013Phase 2Recruiting
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jan 2014
- Primary completion
- Oct 2030
- Countries
- 1
01
Overview
A Phase 2 trial of plerixafor, filgrastim in Idiopathic CD4 lymphocytopenia (ICL), sponsored by National Institute of Allergy and Infectious Diseases. Started Jan 2014; status: recruiting.
02
Drugs
plerixaforfilgrastim
03
Conditions
Idiopathic CD4 lymphocytopenia (ICL)
Beyond the preview
Go deeper on NCT02015013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02015013.